Lixa Pty Ltd
Lixa is a Western Australian biotech company dedicated to solving antimicrobial resistance (AMR) by developing innovative technologies that restore the effectiveness of existing antimicrobials. Their mission is to resolve resistant and recurring microbial infections and contaminations across human, animal, plant, marine, and industrial sectors. They have invented NeoX™, a scalable breakthrough technology to reverse bacterial resistance, which has the potential to significantly impact global health and the economy by 2050. Lixa's approach includes developing resistance breakers compatible with existing antimicrobials, targeting resistant bacteria, and addressing bacterial problems in various environments. The company is engaged in clinical trials, partnerships, and research to advance their solutions and aims to make a substantial humanitarian and economic impact.
Industries
Nr. of Employees
small (1-50)
Products
Resistance‑breaking antibiofilm molecule platform (lead inhaled candidate)
A platform of small molecules that dismantle bacterial biofilms and disable resistance mechanisms to restore the effectiveness of existing antibiotics and disinfectants; lead candidate formulated for inhalation with Phase I safety data.
Resistance‑breaking antibiofilm molecule platform (lead inhaled candidate)
A platform of small molecules that dismantle bacterial biofilms and disable resistance mechanisms to restore the effectiveness of existing antibiotics and disinfectants; lead candidate formulated for inhalation with Phase I safety data.
Services
Collaborative research and commercial partnerships across human health, veterinary, agribusiness, industrial and marine sectors to co‑develop antibiofilm/resistance‑breaking solutions.
Design and management of Phase I first‑in‑human studies assessing safety and tolerability of inhaled formulations, including ethical approvals and clinical site coordination.
Quality management oversight during development and planning for manufacturing ramp‑up to support clinical and commercial supply.
Collaborative research and commercial partnerships across human health, veterinary, agribusiness, industrial and marine sectors to co‑develop antibiofilm/resistance‑breaking solutions.
Design and management of Phase I first‑in‑human studies assessing safety and tolerability of inhaled formulations, including ethical approvals and clinical site coordination.
Quality management oversight during development and planning for manufacturing ramp‑up to support clinical and commercial supply.
Expertise Areas
- Antibiofilm therapeutics development
- Early‑phase clinical development (Phase I)
- Molecular microbiology and biofilm biology
- Antimicrobial synergy screening
Key Technologies
- Antibiofilm small‑molecule platform
- Inhaled drug delivery via nebuliser
- Biofilm disruption and quantification assays
- Synergy screening between antimicrobials
News & Updates
Perth biotech, Lixa, has successfully completed its first clinical human trial which has confirmed the safety and tolerability of inhaled NeoX-101. The trial was conducted at Linear Clinical Research in Perth and showed that NeoX-101 was well tolerated with no serious adverse events, paving the way for further clinical trials and regulatory approval.
Lixa is partnering with The University of Queensland to develop solutions for antimicrobial resistance in animals and the environment, including new antimicrobials for animal use and alternative treatments that do not require antibiotics.
Lixa has received Human Research Ethics Committee approval to commence its first human trial, a Phase I clinical trial assessing the safety and tolerability of NeoX™ in an inhaled formulation, targeting resistant respiratory infections.
Lixa has received an Innovation Booster grant from the Department of Jobs, Tourism, Science and Innovation and the WA Government's New Industries Fund to support the development of an international trademark IP strategy.
Lixa is developing a novel approach to resolve recurring microbial infections and contaminations by making resistant bacteria vulnerable again, with applications across human health, animals, and plants.
Lixa was named a finalist in the WA Innovator of the Year awards in the Wesfarmers Wellbeing category, recognized for its innovative NeoX molecule that disrupts bacterial biofilms.
Perth biotech, Lixa, has successfully completed its first clinical human trial which has confirmed the safety and tolerability of inhaled NeoX-101. The trial was conducted at Linear Clinical Research in Perth and showed that NeoX-101 was well tolerated with no serious adverse events, paving the way for further clinical trials and regulatory approval.
Lixa is partnering with The University of Queensland to develop solutions for antimicrobial resistance in animals and the environment, including new antimicrobials for animal use and alternative treatments that do not require antibiotics.
Lixa has received Human Research Ethics Committee approval to commence its first human trial, a Phase I clinical trial assessing the safety and tolerability of NeoX™ in an inhaled formulation, targeting resistant respiratory infections.
Lixa has received an Innovation Booster grant from the Department of Jobs, Tourism, Science and Innovation and the WA Government's New Industries Fund to support the development of an international trademark IP strategy.
Lixa is developing a novel approach to resolve recurring microbial infections and contaminations by making resistant bacteria vulnerable again, with applications across human health, animals, and plants.
Lixa was named a finalist in the WA Innovator of the Year awards in the Wesfarmers Wellbeing category, recognized for its innovative NeoX molecule that disrupts bacterial biofilms.